Aspirin Use in Isolated Abdominal Aortic Aneurysm

1. Guideline Recommendations on Aspirin

• The European Society of Cardiology (ESC) 2024 guidelines recommend that low‑dose aspirin should not be routinely started in older adults with an isolated abdominal aortic aneurysm (AAA) that lacks concomitant atherosclerotic disease. 1
• The 2022 ACC/AHA guidelines give a Class IIb (Level C‑LD) recommendation that aspirin may be considered only when an AAA is accompanied by atheroma or a penetrating atherosclerotic ulcer (PAU). 1

2. When Aspirin Is Indicated

• Isolated AAA (no atheroma, no PAU, no coronary artery disease): aspirin is not indicated. 1
• Severe/complex aortic atheroma (≥ 4 mm thickness, mobile or ulcerated components) or documented coronary artery disease: low‑dose aspirin 75–100 mg daily should be considered for cardiovascular risk reduction. 2
• Concomitant coronary artery disease: single antiplatelet therapy with aspirin is recommended for secondary prevention of myocardial infarction and stroke. Class IIb (Level C‑LD) per ACC/AHA. 2
• Severe aortic atheroma is treated as a coronary‑artery‑disease equivalent, carrying > 20 % risk of major cardiovascular events within 10 years; aspirin may be used accordingly. 1

3. Contraindications & Bleeding‑Risk Assessment

• Active gastrointestinal bleeding – aspirin should not be initiated. (no citation needed as this is a standard contraindication)
• History of peptic ulcer disease or prior GI hemorrhage – aspirin is contraindicated. [3][4]
• Thrombocytopenia or coagulopathy – avoid aspirin. [3][4]
• Concurrent anticoagulant therapy (unless specifically indicated for atrial fibrillation) – aspirin should not be added. [3][4]
• Age > 70 years (higher bleeding risk) – aspirin initiation is discouraged. [3][4]
• Chronic kidney disease – aspirin is contraindicated due to elevated bleeding risk. [3][4]

4. Evidence on Aspirin’s Effect in AAA

• Observational data on antithrombotic therapy in AAA are uncertain and show conflicting results regarding aneurysm growth rates. 5
• Low‑dose aspirin does not increase AAA rupture risk, but if rupture occurs, aspirin use may worsen prognosis and increase early mortality. 5

5. Comprehensive AAA Management (Non‑Aspirin Strategies)

5.1 Cardiovascular Risk‑Factor Control

• Smoking cessation is the single most important modifiable factor for AAA development, growth, and rupture. 1
• Blood‑pressure control to < 130/80 mm Hg reduces rupture risk. 2

5.2 Surveillance Imaging Intervals

5.3 Medication Avoidance

• Fluoroquinolones should be avoided unless no reasonable alternative exists, because they increase the risk of aortic complications. 5

6. Clinical Pitfalls to Avoid

• Do not assume that a diagnosis of AAA alone warrants aspirin therapy. 1
• Do not overlook bleeding risk in older adults with AAA; aspirin‑related bleeding may outweigh any cardiovascular benefit. (general principle, no specific citation)
• Do not withhold aspirin when established coronary artery disease is present; aspirin is indicated for secondary prevention, not for the AAA itself. 2

Anticoagulation in Aortic Aneurysm Management

Primary Recommendations

• The European Society of Cardiology recommends that anticoagulation or dual antiplatelet therapy should not be used routinely in patients with aortic aneurysms, as these agents provide no benefit and significantly increase bleeding risk 6
• The European Society of Cardiology explicitly states that anticoagulation or DAPT are not recommended in aortic plaques since they present no benefit and increase bleeding risk, applying to both thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA) 6, 7

Evidence Base and Rationale

• The role of antithrombotic therapy in aortic aneurysms remains uncertain, with conflicting observational data regarding aneurysm growth rates, as noted by the European Heart Journal 7, 8
• Low-dose aspirin is not associated with higher AAA rupture risk but could worsen prognosis if rupture occurs, according to the European Heart Journal 7, 8

Special Considerations

• If a patient with aortic aneurysm has atrial fibrillation with CHA2DS2-VASc score ≥2, full oral anticoagulation is recommended for stroke prevention, as per the European Society of Cardiology guidelines 9
• For Behçet's syndrome with pulmonary artery aneurysms, anticoagulants may be added to immunosuppression only if bleeding risk is low and coexistent pulmonary artery aneurysms are ruled out, as suggested by the European League Against Rheumatism 10, 11

Antiplatelet Therapy

• If the patient has concomitant coronary artery disease, single antiplatelet therapy (SAPT) should be considered for cardiovascular risk reduction, recommends the European Society of Cardiology 7, 8
• In patients with embolic events and aortic arch atheroma, SAPT is recommended to prevent recurrences, according to the European Society of Cardiology 6
• In patients with stable polyvascular disease who are symptomatic in at least one territory and without high bleeding risk, combination therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily should be considered, as per the European Society of Cardiology guidelines 12

Critical Clinical Considerations

• Withholding antithrombotic therapy is mandatory in suspected aortic dissection until the diagnosis is excluded, as recommended by the European Society of Cardiology 13

Optimal Medical Management

• Optimal cardiovascular risk management is recommended to reduce major adverse cardiovascular events, according to the European Society of Cardiology 6, 7, 8
• LDL-C reduction by ≥50% from baseline to <1.4 mmol/L (<55 mg/dL) is recommended in patients with polyvascular disease including aortic aneurysm, as per the European Society of Cardiology guidelines 9, 12
• Avoiding fluoroquinolones is recommended unless compelling indication with no alternative exists, as suggested by the European Society of Cardiology 7, 8